Magromag (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA, inhibit carbohydrate metabolism, and disrupt cell‑wall synthesis. These actions result in bacteriostatic or bactericidal effects against common urinary pathogens.

The dosage of Magromag is determined by the prescribing clinician based on the patient’s condition, renal function, and local treatment guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Nitrofurantoin is classified as pregnancy category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Use while breastfeeding should be discussed with a healthcare professional.

To order Magromag, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Magromag (nitrofurantoin) is a nitrofuran antibiotic that offers targeted activity against many common uropathogens, especially Escherichia coli. Compared with broader‑spectrum agents such as trimethoprim‑sulfamethoxazole, nitrofurantoin has a lower risk of promoting resistance but is limited to uncomplicated infections and requires adequate renal function.

Magromag should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Magromag is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to optimise absorption.

Serious risks include pulmonary toxicity (interstitial lung disease), hepatic injury, hemolytic anemia in patients with G6PD deficiency, severe skin reactions such as Stevens‑Johnson syndrome, and peripheral neuropathy. Patients should seek immediate medical attention if they experience respiratory difficulty, jaundice, unusual skin rash, or numbness.

Magromag should be avoided in patients with severe renal impairment (creatinine clearance < 30 mL/min), known hypersensitivity to nitrofurantoin, or a history of G6PD deficiency. Caution is also advised for individuals with a prior history of pulmonary or hepatic reactions to nitrofurantoin.